Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Baqsimi ® (glukagon näspulver)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The NG powder is absorbed passively through the nasal mucosa, and delivery does not require the person to be conscious or to inhale.1,2
Study 1
Participants in one of the adult pivotal studies, Study 1, reported respiratory medical conditions, including cough in 1 participant and oropharyngeal pain in 2 participants. These participants completed the study.3
Concomitant medications for respiratory conditions administered by mouth included codeine and throat lozenges.3
Study 2
Participants in one of the adult pivotal studies, Study 2, reported respiratory medical conditions, including asthma in 5 participants and seasonal allergy in 7 participants.3
Concomitant medications for respiratory conditions administered by mouth included
acetaminophen, phenylephrine, and guaifenesin
albuterol inhaler
cetirizine
fexofenadine
fluticasone oral inhaler
guaifenesin
loratadine, and
montelukast.3
One participant with asthma discontinued from the study prior to completing both dosing visits.3
Pediatric Pivotal Study
Participants who were enrolled in and completed the pediatric pivotal study reported respiratory medical conditions including
asthma, n=5
house dust allergy, n=1, and
seasonal allergy, n=5.3
Concomitant medications for respiratory conditions administered by mouth included
albuterol inhaler
budesonide inhaler
cetirizine
fexofenadine
loratadine, and
montelukast.3
1. Rickels MR, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264-270. https://doi.org/10.2337/dc15-1498
2. Sherr JL, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555-562. https://doi.org/10.2337/dc15-1606
3. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
NG = nasal glucagon (glucagon nasal powder)
Datum fӧr senaste ӧversyn 2019 M09 11